Want to see IN:GLAXO full AI Analyst Report?
Total Valuation
GlaxoSmithKline Pharmaceuticals Limited has a market cap or net worth of ₹491.21B. The enterprise value is ₹359.33K.
Market Cap₹491.21B
Enterprise Value₹359.33K
Share Statistics
GlaxoSmithKline Pharmaceuticals Limited has 169,406,040 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding169,406,040
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
GlaxoSmithKline Pharmaceuticals Limited’s return on equity (ROE) is 0.46 and return on invested capital (ROIC) is 36.25%.
Return on Equity (ROE)0.46
Return on Assets (ROA)0.24
Return on Invested Capital (ROIC)36.25%
Return on Capital Employed (ROCE)0.50
Revenue Per Employee12.32M
Profits Per Employee3.34M
Employee Count3,103
Asset Turnover0.88
Inventory Turnover3.11
Valuation Ratios
The current PE Ratio of GlaxoSmithKline Pharmaceuticals Limited is 46.5. GlaxoSmithKline Pharmaceuticals Limited’s PEG ratio is 3.20.
PE Ratio46.5
PS Ratio10.12
PB Ratio17.06
Price to Fair Value17.06
Price to FCF39.99
Price to Operating Cash Flow270.30
PEG Ratio3.20
Income Statement
In the last 12 months, GlaxoSmithKline Pharmaceuticals Limited had revenue of 38.22B and earned 10.36B in profits. Earnings per share was 61.15.
Revenue38.22B
Gross Profit16.65B
Operating Income12.60B
Pretax Income14.06B
Net Income10.36B
EBITDA14.75B
Earnings Per Share (EPS)61.15
Cash Flow
In the last 12 months, operating cash flow was 1.84B and capital expenditures -170.40M, giving a free cash flow of 1.67B billion.
Operating Cash Flow1.84B
Free Cash Flow1.67B
Free Cash Flow per Share9.84
Dividends & Yields
GlaxoSmithKline Pharmaceuticals Limited pays an annual dividend of ₹57, resulting in a dividend yield of 1.94%
Dividend Per Share₹57
Dividend Yield1.94%
Payout Ratio94.92%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.69
52-Week Price Change7.35%
50-Day Moving Average2.53K
200-Day Moving Average2.42K
Relative Strength Index (RSI)69.78
Average Volume (3m)1.83K
Important Dates
GlaxoSmithKline Pharmaceuticals Limited upcoming earnings date is Nov 5, 2026, TBA (Confirmed).
Last Earnings DateAug 3, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
GlaxoSmithKline Pharmaceuticals Limited as a current ratio of 2.03, with Debt / Equity ratio of 0.00%
Current Ratio2.03
Quick Ratio1.77
Debt to Market Cap0.00
Net Debt to EBITDA-0.72
Interest Coverage Ratio461.50
Taxes
In the past 12 months, GlaxoSmithKline Pharmaceuticals Limited has paid 3.70B in taxes.
Income Tax3.70B
Effective Tax Rate0.26
Enterprise Valuation
GlaxoSmithKline Pharmaceuticals Limited EV to EBITDA ratio is 25.49, with an EV/FCF ratio of 38.89.
EV to Sales9.84
EV to EBITDA25.49
EV to Free Cash Flow38.89
EV to Operating Cash Flow36.78
Balance Sheet
GlaxoSmithKline Pharmaceuticals Limited has ₹27.57B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of ₹27.57B billion.
Cash & Marketable Securities₹27.57B
Total Debt₹0.00
Net Cash₹27.57B
Net Cash Per Share₹162.73
Tangible Book Value Per Share₹133.45
Margins
Gross margin is 51.97%, with operating margin of 32.97%, and net profit margin of 27.11%.
Gross Margin51.97%
Operating Margin32.97%
Pretax Margin36.79%
Net Profit Margin27.11%
EBITDA Margin38.60%
EBIT Margin32.97%
Analyst Forecast
The average price target for GlaxoSmithKline Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast5.75%
EPS Growth Forecast12.41%